Type to search

Health Care News

FDA approves AstraZeneca diabetes drug

Avatar photo

WILMINGTON, Del.—The U.S. Food and Drug Administration has approved AstraZeneca’s QTERN for the treatment of type 2 diabetes.

The new medicine aims to improve blood-sugar-level control in adults with type 2 diabetes who have inadequate control with dapagliflozin or who are already treated with dapagliflozin and saxagliptin.

“Type 2 diabetes is a complex disease that is at epidemic proportions, affecting more than 29 million people in the US alone,” said Elisabeth Bjork, the company vice president who heads cardiovascular and metabolic disease medicines.

The drug improves glycemic control through a once-daily tablet.

Get the free DBT email newsletter  

Follow the people, companies and issues that matter most to business in Delaware.


You Might also Like

Leave a Comment

Your email address will not be published. Required fields are marked *

Premier Digital Partners

© 2023 Delaware Business Times